23,710 Shares of LivaNova PLC $LIVN Purchased by Alamar Capital Management LLC

Key Points

• Alamar Capital Management opened a position in LivaNova, buying 23,710 shares valued at approximately $1.81 million. Institutional investors and hedge funds own 97.64% of the company.
• LivaNova beat quarterly estimates, reporting EPS of $1.23 versus $1.06 expected and revenue of $393.15 million, up 9.9% year over year.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $99.56. Meanwhile, company insiders sold 7,450 shares worth about $592,000 over the last quarter.

Alamar Capital Management LLC acquired a new stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 23,710 shares of the company's stock, valued at approximately $1,814,000.

A number of other hedge funds also recently bought and sold shares of the business. Allworth Financial LP lifted its position in LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company's stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. Root Financial Partners LLC bought a new position in shares of LivaNova in the 3rd quarter worth about $32,000. Farther Finance Advisors LLC raised its holdings in shares of LivaNova by 59.7% during the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company's stock valued at $35,000 after buying an additional 169 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in LivaNova in the 2nd quarter valued at about $37,000. Finally, Sterling Capital Management LLC boosted its stake in LivaNova by 34.6% in the 3rd quarter. Sterling Capital Management LLC now owns 1,261 shares of the company's stock worth $96,000 after purchasing an additional 324 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

LIVN has been the subject of a number of recent research reports. Raymond James Financial set a $120.00 target price on LivaNova in a report on Wednesday. Jefferies Financial Group restated a "buy" rating on shares of LivaNova in a report on Wednesday. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Needham & Company LLC increased their price target on shares of LivaNova from $93.00 to $112.00 and gave the stock a "buy" rating in a research note on Wednesday. Finally, Piper Sandler reiterated an "overweight" rating and issued a $90.00 price target (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $99.56.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 3,500 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total transaction of $273,035.00. Following the transaction, the director owned 4,434 shares in the company, valued at approximately $345,896.34. The trade was a 44.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Brooke Story sold 2,300 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director owned 7,488 shares of the company's stock, valued at approximately $609,672.96. This trade represents a 23.50% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 7,450 shares of company stock worth $591,839 over the last quarter. 0.35% of the stock is owned by company insiders.

LivaNova Stock Down 1.3%

LivaNova stock opened at $89.99 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The firm has a market capitalization of $4.96 billion, a PE ratio of 30.00 and a beta of 0.91. LivaNova PLC has a fifty-two week low of $49.73 and a fifty-two week high of $99.38. The company's 50-day moving average is $79.27 and its 200-day moving average is $73.54.

LivaNova (NASDAQ:LIVN - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.06 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The company had revenue of $393.15 million for the quarter, compared to analyst estimates of $381.13 million. During the same period in the previous year, the company posted $1.11 EPS. The firm's revenue for the quarter was up 9.9% compared to the same quarter last year. Sell-side analysts anticipate that LivaNova PLC will post 3.79 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC NASDAQ: LIVN is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company's Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.